Acura Pharmaceuticals (ACUR): Price and Financial Metrics
GET POWR RATINGS... FREE!
ACUR Stock Summary
- The capital turnover (annual revenue relative to shareholder's equity) for ACUR is 16.63 -- better than 98.25% of US stocks.
- With a year-over-year growth in debt of -94.83%, Acura Pharmaceuticals Inc's debt growth rate surpasses only 1.94% of about US stocks.
- Revenue growth over the past 12 months for Acura Pharmaceuticals Inc comes in at -44.87%, a number that bests only 3.61% of the US stocks we're tracking.
- Stocks with similar financial metrics, market capitalization, and price volatility to Acura Pharmaceuticals Inc are ADXS, ALV, OCFT, GILT, and NEU.
- Visit ACUR's SEC page to see the company's official filings. To visit the company's web site, go to www.acurapharm.com.
ACUR Valuation Summary
- In comparison to the median Healthcare stock, ACUR's EV/EBIT ratio is 216.04% lower, now standing at -34.
- ACUR's price/sales ratio has moved up 14 over the prior 243 months.
- ACUR's price/sales ratio has moved up 14 over the prior 243 months.
Below are key valuation metrics over time for ACUR.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| ACUR | 2021-08-31 | 16.1 | 100.5 | -24.5 | -34.0 |
| ACUR | 2021-08-30 | 15.0 | 93.7 | -22.8 | -31.7 |
| ACUR | 2021-08-27 | 16.1 | 100.5 | -24.5 | -34.0 |
| ACUR | 2021-08-26 | 14.7 | 91.9 | -22.4 | -31.1 |
| ACUR | 2021-08-25 | 13.7 | 85.3 | -20.8 | -28.9 |
| ACUR | 2021-08-24 | 15.0 | 93.7 | -22.8 | -31.7 |
ACUR Growth Metrics
- Its 4 year price growth rate is now at -88.99%.
- Its 3 year net cashflow from operations growth rate is now at 57.03%.
- Its 5 year net cashflow from operations growth rate is now at 101.65%.
The table below shows ACUR's growth in key financial areas (numbers in millions of US dollars).
| Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
|---|---|---|---|
| 2021-09-30 | 2.245 | -0.396 | -1.151 |
| 2021-06-30 | 2.385 | -1.132 | -1.567 |
| 2021-03-31 | 3.123 | -1.379 | -0.872 |
| 2020-12-31 | 3.57 | -0.719 | -1.208 |
| 2020-09-30 | 4.072 | -0.117 | -0.81 |
| 2020-06-30 | 4.986 | 1.028 | 0.068 |
ACUR Stock Price Chart Interactive Chart >
ACUR Price/Volume Stats
| Current price | $0.53 | 52-week high | $0.75 |
| Prev. close | $0.53 | 52-week low | $0.29 |
| Day low | $0.49 | Volume | 1,000 |
| Day high | $0.53 | Avg. volume | 7,230 |
| 50-day MA | $0.45 | Dividend yield | N/A |
| 200-day MA | $0.52 | Market Cap | 34.66M |
Acura Pharmaceuticals (ACUR) Company Bio
Acura Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the research, development, and commercialization of technologies and products to address safe use of medications in the United States. It offers Oxaydo tablets, a Schedule II narcotic indicated for the management of acute and chronic moderate to severe pain; and Nexafed products, which are pseudoephedrine and acetaminophen tablets that are used as nasal decongestants in various non-prescription and prescription cold, sinus, and allergy products. The company has six additional opioid products in various stages of formulation development. Acura Pharmaceuticals, Inc. has collaboration and license agreements with Egalet US, Inc.; and Egalet Ltd. to manufacture and commercialize Oxaydo products worldwide; and development and commercialization agreement with Abuse Deterrent Pharma, LLC to develop LTX-03, an immediate-release tablets utilizing LIMITx technology. The company was founded in 1935 and is based in Palatine, Illinois.
Latest ACUR News From Around the Web
Below are the latest news stories about Acura Pharmaceuticals Inc that investors may wish to consider to help them evaluate ACUR as an investment opportunity.
Acura, Abuse Deterrent Pharmaceuticals amend license deal for pain drug LIMITx LTX-03Acura Pharmaceuticals (ACUR) amended a license, development and commercialization agreement for its product candidate LIMITx LTX-03 with Abuse Deterrent Pharmaceuticals to extend the… |
Acura Pharmaceuticals and AD Pharma Amend License to LIMITx™ LTX-03Amendment Extends NDA Acceptance DatePALATINE, Ill., March 01, 2022 (GLOBE NEWSWIRE) -- Acura Pharmaceuticals, Inc. (OTCQB: ACUR) today announced an amendment to its License, Development and Commercialization Agreement (“Agreement”) regarding Acura’s LIMITx™ LTX-03 product candidate with Abuse Deterrent Pharmaceuticals, LLC (“AD Pharma”) to extend the FDA Acceptance Date for LTX-03 (“NDA Acceptance Date”) to December 31, 2022. The Company expects to complete clinical studies and other required s |
Acura Pharmaceuticals Provides Development Update on LTX-03PALATINE, Ill., Feb. 14, 2022 (GLOBE NEWSWIRE) -- Acura Pharmaceuticals, Inc. (OTCQB: ACUR) today announced that the LTX-03 (hydrocodone bitartrate and acetaminophen) tablets using Acura’s LIMITx technology manufactured in the three New Drug Application (“NDA”) required registration batches successfully passed testing at the six month time point in an ongoing shelf life study when stored at normal temperature and humidity conditions, also known as controlled room temperature (“CRT”). The patente |
Acura Pharmaceuticals (OTCMKTS:ACUR) Shares Pass Above 200 Day Moving Average of $0.55Shares of Acura Pharmaceuticals, Inc. (OTCMKTS:ACUR) passed above its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $0.55 and traded as high as $0.55. Acura Pharmaceuticals shares last traded at $0.55, with a volume of 2,404 shares traded. The company has a quick ratio of 0.86, a [] |
Acura Pharmaceuticals reports Q3 resultsNo summary available. |
ACUR Price Returns
| 1-mo | -1.85% |
| 3-mo | 18.57% |
| 6-mo | 0.47% |
| 1-year | 32.63% |
| 3-year | 140.91% |
| 5-year | 6.00% |
| YTD | 6.00% |
| 2021 | 138.10% |
| 2020 | -8.70% |
| 2019 | 100.17% |
| 2018 | -71.55% |
| 2017 | -47.55% |
Loading social stream, please wait...